Literature DB >> 22234539

Radiosensitizing effect of epothilone B on human epithelial cancer cells.

T Baumgart1, G Klautke, S Kriesen, S A Kuznetsov, D G Weiss, R Fietkau, G Hildebrandt, K Manda.   

Abstract

BACKGROUND: A combined modality treatment employing radiation and chemotherapy plays a central role in the management of solid tumors. In our study, we examined the cytotoxic and radiosensitive effect of the microtubule stabilizer epothilone B on two human epithelial tumor cell lines in vitro and its influence on the microtubule assembly.
METHODS: Cancer cells were treated with epothilone B in proliferation assays and in combination with radiation in colony-forming assays. For the analysis of ionizing radiation-induced DNA damage and the influence of the drug on its repair a γH2AX foci assay was used. To determine the effect of epothilone B on the microtubule assembly in cells and on purified tubulin, immunofluorescence staining and tubulin polymerization assay, respectively, were conducted.
RESULTS: Epothilone B induced a concentration- and application-dependent antiproliferative effect on the cells, with IC(50) values in the low nanomolar range. Colony forming assays showed a synergistic radiosensitive effect on both cell lines which was dependent on incubation time and applied concentration of epothilone B. The γH2AX assays demonstrated that ionizing radiation combined with the drug resulted in a concentration-dependent increase in the number of double-strand breaks and suggested a reduction in DNA repair capacity. Epothilone B produced enhanced microtubule bundling and abnormal spindle formation as revealed by immunofluorescence microscopy and caused microtubule formation from purified tubulin.
CONCLUSION: The results of this study showed that epothilone B displays cytotoxic antitumor activity at low nanomolar concentrations and also enhances the radiation response in the tumor cells tested; this may be induced by a reduced DNA repair capacity triggered by epothilone B. It was also demonstrated that epothilone B in fact targets microtubules in a more effective manner than paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234539     DOI: 10.1007/s00066-011-0029-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  47 in total

1.  Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.

Authors:  Jie-Guang Chen; Susan Band Horwitz
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 2.  Stage III: definitive chemoradiotherapy.

Authors:  Rainer Fietkau; Sabine Semrau
Journal:  Front Radiat Ther Oncol       Date:  2009-11-24

3.  Microtubule-associated proteins and microtubule-based translocators have different binding sites on tubulin molecule.

Authors:  V I Rodionov; F K Gyoeva; A S Kashina; S A Kuznetsov; V I Gelfand
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

4.  Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.

Authors:  Hendrik Andreas Wolff; Steffen Hennies; Markus Karl Alfred Herrmann; Margret Rave-Fränk; David Eickelmann; Patricia Virsik; Klaus Jung; Markus Schirmer; Michael Ghadimi; Clemens Friedrich Hess; Robert Michael Hermann; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

5.  The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration.

Authors:  T K Yeung; C Germond; X Chen; Z Wang
Journal:  Biochem Biophys Res Commun       Date:  1999-09-24       Impact factor: 3.575

6.  Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays.

Authors:  Alex S Kiselyov; Marina N Semenova; Natalya B Chernyshova; Andrei Leitao; Alexandr V Samet; Konstantine A Kislyi; Mikhail M Raihstat; Tudor Oprea; Heiko Lemcke; Margaréta Lantow; Dieter G Weiss; Nazli N Ikizalp; Sergei A Kuznetsov; Victor V Semenov
Journal:  Eur J Med Chem       Date:  2010-01-14       Impact factor: 6.514

7.  Omega-3 fatty acid supplementation in cancer therapy : does eicosapentanoic acid influence the radiosensitivity of tumor cells?

Authors:  Katrin Manda; Stephan Kriesen; Guido Hildebrandt; Rainer Fietkau; Gunther Klautke
Journal:  Strahlenther Onkol       Date:  2011-01-18       Impact factor: 3.621

8.  Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery : early results and toxicity.

Authors:  Bernhard J Leibl; Stephanie Vitz; Wolfgang Schäfer; Martin Alfrink; Andreas Gschwendtner; Gerhard G Grabenbauer
Journal:  Strahlenther Onkol       Date:  2011-03-24       Impact factor: 3.621

9.  Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

Authors:  Barbara Hofstetter; Van Vuong; Angela Broggini-Tenzer; Stephan Bodis; Ilja F Ciernik; Doriano Fabbro; Markus Wartmann; Gerd Folkers; Martin Pruschy
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

10.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

View more
  2 in total

1.  The effect of resveratrol in combination with irradiation and chemotherapy: study using Merkel cell carcinoma cell lines.

Authors:  G Heiduschka; C Lill; R Seemann; M Brunner; R Schmid; R Houben; J Bigenzahn; D Thurnher
Journal:  Strahlenther Onkol       Date:  2013-11-08       Impact factor: 3.621

2.  A genomic Multiprocess survey of machineries that control and link cell shape, microtubule organization, and cell-cycle progression.

Authors:  Veronika Graml; Xenia Studera; Jonathan L D Lawson; Anatole Chessel; Marco Geymonat; Miriam Bortfeld-Miller; Thomas Walter; Laura Wagstaff; Eugenia Piddini; Rafael E Carazo Salas
Journal:  Dev Cell       Date:  2014-10-27       Impact factor: 12.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.